trimetrexate and Infection, Toxoplasma gondii
trimetrexate has been researched along with Infection, Toxoplasma gondii in 6 studies
Trimetrexate: A nonclassical folic acid inhibitor through its inhibition of the enzyme dihydrofolate reductase. It is being tested for efficacy as an antineoplastic agent and as an antiparasitic agent against PNEUMOCYSTIS PNEUMONIA in AIDS patients. Myelosuppression is its dose-limiting toxic effect.
Research Excerpts
| Excerpt | Relevance | Reference |
|---|---|---|
| "A safer treatment for toxoplasmosis would be achieved by improving the selectivity and potency of dihydrofolate reductase (DHFR) inhibitors, such as pyrimethamine (1), for Toxoplasma gondii DHFR ( TgDHFR) relative to human DHFR ( hDHFR)." | 3.91 | Discovery of Selective Toxoplasma gondii Dihydrofolate Reductase Inhibitors for the Treatment of Toxoplasmosis. ( Barks, J; Brockman, A; Gould, J; Hopper, AT; Radke, JB; Sibley, LD; Thomas, S; Wise, A; Zou, Y, 2019) |
| "Trimetrexate is an agent that does not require uptake by the folate carrier transport system, a major mechanism of cellular resistance both in vitro and in vivo." | 2.39 | Clinical pharmacokinetics and pharmacology of trimetrexate. ( DeLap, RJ; Marshall, JL, 1994) |
Research
Studies (6)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (16.67) | 18.7374 |
| 1990's | 3 (50.00) | 18.2507 |
| 2000's | 1 (16.67) | 29.6817 |
| 2010's | 1 (16.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
Authors
| Authors | Studies |
|---|---|
| Piper, JR | 1 |
| Johnson, CA | 1 |
| Krauth, CA | 1 |
| Carter, RL | 1 |
| Hosmer, CA | 1 |
| Queener, SF | 2 |
| Borotz, SE | 1 |
| Pfefferkorn, ER | 1 |
| Gangjee, A | 1 |
| Adair, OO | 1 |
| Hopper, AT | 1 |
| Brockman, A | 1 |
| Wise, A | 1 |
| Gould, J | 1 |
| Barks, J | 1 |
| Radke, JB | 1 |
| Sibley, LD | 1 |
| Zou, Y | 1 |
| Thomas, S | 1 |
| Marshall, JL | 1 |
| DeLap, RJ | 1 |
| Allegra, CJ | 1 |
| Kovacs, JA | 1 |
| Drake, JC | 1 |
| Swan, JC | 1 |
| Chabner, BA | 1 |
| Masur, H | 1 |
Reviews
1 review available for trimetrexate and Infection, Toxoplasma gondii
| Article | Year |
|---|---|
Clinical pharmacokinetics and pharmacology of trimetrexate.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Dose-Response Rel | 1994 |
Other Studies
5 other studies available for trimetrexate and Infection, Toxoplasma gondii
| Article | Year |
|---|---|
Lipophilic antifolates as agents against opportunistic infections. 1. Agents superior to trimetrexate and piritrexim against Toxoplasma gondii and Pneumocystis carinii in in vitro evaluations.
Topics: Animals; Anti-Infective Agents; Folic Acid Antagonists; Opportunistic Infections; Pneumocystis; Pneu | 1996 |
Synthesis and biological evaluation of 2,4-diamino-6-(arylaminomethyl)pyrido[2,3-d]pyrimidines as inhibitors of Pneumocystis carinii and Toxoplasma gondii dihydrofolate reductase and as antiopportunistic infection and antitumor agents.
Topics: Animals; Anti-Infective Agents; Antineoplastic Agents; Cell Line; Cell Line, Tumor; Cricetinae; Drug | 2003 |
Discovery of Selective Toxoplasma gondii Dihydrofolate Reductase Inhibitors for the Treatment of Toxoplasmosis.
Topics: Animals; Antiparasitic Agents; Dogs; Female; Folic Acid Antagonists; Humans; Madin Darby Canine Kidn | 2019 |
Drugs for AIDS and associated infections.
Topics: Acquired Immunodeficiency Syndrome; AIDS-Related Opportunistic Infections; Amphotericin B; Antifunga | 1995 |
Potent in vitro and in vivo antitoxoplasma activity of the lipid-soluble antifolate trimetrexate.
Topics: Animals; Folic Acid Antagonists; Kinetics; Lacticaseibacillus casei; Mice; Mice, Inbred BALB C; Quin | 1987 |